Battery Future Acquisition Corp Class A 주식 (OTC: BFACF)

에 대한 최신 뉴스 Battery Future Acquisition Corp Class A (OTC:BFACF) 주식

Battery Future Acquisition Corp Class A

The Company is now preparing for the enrollment of the first patient to receive Clearmind's innovative treatment as part of the trial
Vancouver, Canada, April 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the initiation of its U.S. clinical trial site at the Yale School of Medicine's Department of Psychiatry. With this initiation, the Company has now activated all planned sites for its clinical trial for its Phase I/IIa clinical trial in Alcohol Use Disorder ("AUD") and can begin patient enrollment .Clearmind has completed all necessary preparations for the clinical trial, including obtaining Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to start the Phase I/IIa clinical trial, Institutional Review Board (IRB) approvals from each clinical site, launch of its Electronic Data Capture (EDC) system to support the clinical trial and the arrival of its drug candidate, CMND-100, into the United States following successful manufacturing.
The trial in Yale School of Medicine's Department of Psychiatry will be led by Dr. Anahita Bassir Nia, M.D., a specialist in substance abuse, including alcohol abuse. The trial will also be conducted at the Johns Hopkins University School of Medicine in the U.S. and at the IMCA Center in Israel.

News

CMND

Clearmind Medicine Announces Initiation of Alcohol Use Disorder Phase I/IIa Clinical Trial At All Current Clinical Sites

<figure class="wp-block-image size-full"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/23075010/%E8%9E%A2%E5%B9%95%E6%88%AA%E5%9C%96-2025-04-16-%E4%B8%8A%E5%8D%887.46.19-1.jpg" alt="" class="wp-image-11378" /></figure>
China's largest underwriter of Hong Kong listings helped its clients to raise $3.84 billion last year, as it reportedly gets set to sponsor another blockbuster IPO by battery giant CATL

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>CICC said its net profit rose between 50% and 70% in the first quarter, as it capitalized on rebounds in the Hong Kong IPO and stock markets</li>
<li>The leading investment bank's valuation is significantly lower than its U.S. peers due to its weaker return on equity</li>
</ul>
Stock markets in Hong Kong, Shanghai and Shenzhen have been on a roll the last two quarters, buoyed by Beijing's nearly nonstop efforts to support a flagging Chinese economy. The resulting euphoria has not only lifted many shares, but also rekindled a stalled IPO market, to the relief of investment banks that rely on fees from new listings as a major revenue source.
That lift was a major engine behind a recent&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0410/2025041001337.pdf">positive profit alert</a>&nbsp;from leading Chinese investment bank&nbsp;China International Capital Corp. Ltd.&nbsp;(3908.HK; 601995.SH), or CICC, which forecast its profit jumped up to 70% year-on-year in the first quarter.
CICC made financial history at its founding in 1995 as China's first foreign-invested investment bank, signaling the country's intent to enter the investment banking big leagues. Its initial investors included global giant Morgan Stanley (MS.US) and Singapore's GIC, alongside domestic majors like China Construction Bank (0939.HK; 600939.SH) and the China National Investment and Guaranty Corp. It was the first Mainland investment bank in Hong Kong with its entry to the market in 1997, and helped to underwrite the landmark IPO by leading wireless carrier China Mobile that year. In later listed itself in Hong Kong in 2015, and went public in Shanghai as well in 2020.
According to its announcement earlier this month, CICC said it expects to report a net profit of between 1.86 billion yuan ($254 million) and 2.11 billion yuan for the first quarter of 2025, up between 50% and 70% year-on-year. It attributed the jump to similar revenue increases for its wealth management and securities businesses, but provided little additional detail.
The company's revenue comes primarily from three sources: transaction fees and commissions, interest income and investment proceeds. Transaction fees and commissions accounted for 40% of its total in 2023 and 2024, followed by interest income at nearly 28% both years.&nbsp;&nbsp;
The company charges transaction fees and commissions in its brokerage, investment banking and asset management businesses. Its brokerage arm mainly buys and sells securities for clients, while its investment banking arm underwrites equity financing such as IPOs and secondary offerings, as well as debt and structural financing. It also has an arm that collects fees from providing asset management services.
The strong stock market rallies in Hong Kong, Shanghai and Shenzhen were obvious catalysts for the company's brokerage business in the first quarter. But its investment banking arm that caters to IPO clients is also an important contributor, providing 9.6% and 11.2% of the company's total revenue in 2023 and 2024, respectively. CICC's strongest suit is in helping Chinese enterprises list overseas, with Hong Kong often as their preferred location.
CICC participated in 19 such listings in Hong Kong last year that raised a cumulative $3.84 billion, making it the market's top player for such fundraising. Its clients included home appliance giant Midea Group, Mao Geping Cosmetics and bubble tea chain Chabaidao, to name a few. Among its listings, the company was the bookrunner or main underwriter for nine of the deals it helped to list, ranking second in that category, helping its clients to raise close to $1.25 billion.
CICC also has global aspirations and is active outside the Mainland and Hong Kong. Last year it helped three companies to go public in New York. The total value of listings for which it was the main underwriter reached $87 million, enough to make the company China's top securities firm in that regard, but also showing how limited Chinese underwriters have been in their quest to become truly global players.
While Hong Kong IPOs boomed toward the end of last year, a more muted performance in the A-share markets in Shanghai and Shenzhen translated to only six projects in which CICC was the main underwriter last year, down by 11 from 2023. Its fundraising for those clients totaled 3.59 billion yuan ($492 million), down by nearly 90% year-on-year and accounting for only 5.3% of the value of deals completed on the A-share markets last year. It competes with a big field of well-established domestic underwriters at home, with the result that it was only the eighth largest underwriter for new A-share listings last year.
<h4 class="wp-block-heading">Rebounding Hong Kong IPO market</h4>
In stark contrast to lethargy on Mainland stock markets last year, where the regulator has slowed new listings to support the market, Hong Kong IPO activity has taken off since last fall. A total of 15 IPOs were completed in the market during the first quarter, raising a total of HK$17.7 billion ($2.28 billion), up fourfold year-on-year and the highest first-quarter level since 2021, according to accounting firm KPMG. As many as 120 companies have filed for Hong Kong IPOs so far this year, 34 more than the 86 in the pipeline at the end of last year.
The bustling market has generated strong demand for CICC's underwriting services. Among those, the company has reportedly been selected as one of the cosponsors for a massive Hong Kong listing by battery giant CATL, whose shares are already traded in Shenzhen, which could raise $5 billion or more. It was also an underwriter for Chinese premium tea chain Chagee's U.S. listing that raised $400 million last week. The company's strong international ties also make it a strong candidate for future listings by companies like fast fashion sensation Shein, which is reportedly preparing to list in London, and Alibaba's Ant Group financial affiliate.
While CICC's profit fell by 7.5% last year to 5.69 billion yuan, the figure is expected to return to positive growth this year on momentum in the company's major markets, according to Bloomberg data. Analysts expect the company's net profit to grow by 20.7% this year to 6.87 billion yuan. CICC's Hong Kong stock currently trades at a price-to-book (P/B) ratio of 0.57 times, much lower than foreign peers like&nbsp;Goldman Sach&nbsp;(GS.US) at 1.4 times,&nbsp;Morgan Stanley's&nbsp;1.7 times and&nbsp;JPMorgan's&nbsp;(JPM.US) 2 times.
That said, CICC's expected return on equity (ROE) stands at just 6.6%, compared with figures in the 13% to 15% range for Goldman Sachs, Morgan Stanley and JPMorgan. Such underperformance could explain CICC's lower P/B ratio than its foreign peers, which is a problem common to Chinese companies with low valuations. Accordingly, CICC will need to raise its profitability and ROE if it hopes to catch up with its international peers.

Asia

Equities

IPOs

Opinion

Undervalued CICC Banks On Hong Kong IPO Activity Pickup

B of A Securities analyst Carlos Peyrelongue upgrades Loma Negra Cia Industria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOMA#NYSE">LOMA</a>) from Neutral to Buy and raises the price target from $11.5 to $14.

Upgrades

Price Target

Analyst Ratings

LOMA

B of A Securities Upgrades Loma Negra Cia Industria to Buy, Raises Price Target to $14

Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) will release third-quarter earnings results before the <a href="https://www.benzinga.com/quote/PG/earnings">opening bell on Thursday, April 24.</a>
Analysts expect the Cincinnati, Ohio-based company to report quarterly earnings at $1.53 per share, up from $1.52 per share in the year-ago period. Procter &amp; Gamble projects to report quarterly revenue at $20.15 billion, compared to $20.2 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Tuesday, RBC Capital analyst Nik Modi reiterated Procter &amp; Gamble with a Sector Perform rating and maintained a $164 price target.
With the recent buzz around Procter &amp; Gamble, some investors may be eyeing potential gains from the company's dividends too. Currently, Procter &amp; Gamble offers an annual dividend yield of 2.52%. That&#8217;s a quarterly dividend amount of $1.06 per share ($4.227 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $238,222 or around 1,419 shares. For a more modest $100 per month or $1,200 per year, you would need $47,678 or around 284 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.227 in this case). So, $6,000 / $4.227 = 1,419 ($500 per month), and $1,200 / $4.227 = 284 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
PG Price Action: Shares of Procter &amp; Gamble gained 1.3% to close at $167.88 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44920101/top-2-tech-and-telecom-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech And Telecom Stocks You May Want To Dump This Quarter</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Procter & Gamble Stock Ahead Of Q3 Earnings

The world's largest <a target="_blank" href="https://www.benzinga.com/topic/mining" rel="noreferrer noopener">miner</a>, BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>), is reportedly preparing for a leadership transition as CEO Mike Henry's tenure approaches its expected conclusion.
While no formal announcement has been made, company insiders suggested the board could initiate the succession process soon, with a potential handover in early 2026.
According to information the company's insiders shared <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-23/bhp-prepares-to-start-succession-process-for-mining-s-top-job" rel="noreferrer noopener">with</a> Bloomberg, three candidates are at the forefront of the succession process.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/44709462" rel="noreferrer noopener">Miners Urge Chile To Cut Bureaucracy Before Country Loses Copper Leadership</a>
Geraldine Slattery, who currently oversees BHP's Australian operations, brings extensive experience, having previously managed the company's oil and gas division before its merger with Woodside.
Chief Financial Officer Vandita Pant, a former banker who joined BHP in 2016, has risen rapidly with her financial expertise. Then, there is Ragnar Udd, the commercial chief who has driven the success of BHP's copper business in the Americas.
Selecting either Slattery or Pant would mean that BHP would have its first female CEO in its 140-year history.
Henry assumed the top job in January 2020, taking over from Andrew Mackenzie, who had streamlined BHP's portfolio during a seven-year tenure. Thus, Henry's potential six-year term would align with his predecessor's.
As a company veteran of three decades, Henry previously led BHP's Australian minerals division and held key roles in operations, marketing, and technology.
Under his leadership, significant milestones have occurred, including the exit from petroleum through the Woodside merger, the simplification of BHP's dual-listed structure, and the approval of the massive Jansen potash project in Canada.
However, his boldest move, <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/39068033/time-runs-out-for-bhp-deal-49-billion-acquisition-of-anglo-american-proves-too-complex-to-solve" rel="noreferrer noopener">a $49 billion bid</a> for Anglo American, ultimately collapsed when the target rejected the offer as too complex. This dealt a blow to BHP's copper growth ambition, prompting upper management to seek a solution in a <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition" rel="noreferrer noopener">joint venture with </a><a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition" rel="noreferrer noopener">Lundin</a>.
Henry's successor will inherit both opportunities and challenges. The firm is committing billions to expand in future-facing commodities like copper and potash while maintaining iron ore as its core business.
Still, mining capex is notoriously high, and with nearly $20 billion of debt on the balance sheet, the company is already near the upper limit of its debt targets.
The iron ore business, which delivered 290 million tons in 2024, faces particular headwinds. Analysts at Goldman Sachs forecast prices could slump to <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44651093/iron-ore-set-to-slide-further-as-trump-tariffs-china-slowdown-collide-goldman-says" rel="noreferrer noopener">$84 per ton</a> by late 2025 amid oversupply concerns and softening Chinese demand, while BMI anticipates the oversupply could continue till the end of the decade.
Price Action: BHP stock is up 3.06% to $49.11 premarket at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/44932257/billionaire-john-paulson-buys-800-million-stake-in-alaskan-gold-mine-as-gold-hits-record-highs" target="_blank" rel="noreferrer noopener">Billionaire John Paulson Buys $800 Million Stake In Alaskan Gold Mine As Gold Hits Record Highs</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Large Cap

Rumors

Commodities

Management

Media

World's Largest Miner BHP Quietly Prepares For CEO Succession

Baird analyst Jeffrey Meuler maintains Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) with a Outperform and lowers the price target from $575 to $525.

Baird Maintains Outperform on Moodys, Lowers Price Target to $525

WIIM

BMRA

Biomerica shares are trading higher after the United Arab Emirates Ministry of Health and Prevention approved for sale its Fortel Ulcer Test for the detection of H. pylori infection.

Baird analyst Rob Oliver maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Outperform and lowers the price target from $54 to $37.

KVYO

Baird Maintains Outperform on Klaviyo, Lowers Price Target to $37

TSLA

Tesla shares are trading higher after the company reported Q1 results and CEO Elon Musk indicated his time allocation to DOGE would drop. Additionally, Wedbush raised its price target from $315 to $350.

<ul>
<li>10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancer</li>
<li>Approximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogen</li>
<li>This test empowers healthcare providers with fast, accessible testing across the UAE &nbsp;</li>
</ul>
IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>), a global provider of advanced diagnostic solutions, announced today that its Fortel&#xAE; Ulcer Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval enables Biomerica to introduce its rapid point-of-care test for Helicobacter pylori (H. pylori) infection across the UAE—a region where gastrointestinal diseases are a growing public health concern.
The Fortel&#xAE; Ulcer Test is a simple, quick and user-friendly diagnostic tool that detects antibodies to H. pylori, a bacterium known to cause peptic ulcer disease, dyspepsia, and gastric cancer. The test delivers accurate results in just 10 minutes.

Biotech

Global

General

Biomerica's Fortel Ulcer Test Approved For Sale In UAE, Enabling Rapid 10-Minute Detection Of Helicobacter pylori, A Class 1 Carcinogen Linked To 80% Of Gastric Cancer Cases—Offering Fast, Accessible Diagnostic Tool Amid Growing Regional GI Health Concerns

Chardan Capital analyst Daniil Gataulin maintains Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) with a Buy and maintains $4 price target.

Chardan Capital Maintains Buy on Unity Biotechnology, Maintains $4 Price Target

NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) filed its 510(k) submission to the FDA for trigeminal nerve ablation on Wednesday, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">earlier than previously guided</a>.&nbsp;
NeuroOne Medical is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation.
In March, the company accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025. The company had previously projected a submission by the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44245575/neuroone-accelerates-timeline-of-510-k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-s" rel="noreferrer noopener">end of June 2025</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44937940/abbvies-pipeline-may-be-a-2026-story-but-analyst-likes-the-setup-now" rel="noreferrer noopener">AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now</a>
The submission leverages the company's proprietary OneRF Ablation System RF generator platform for trigeminal neuralgia, a chronic pain condition affecting approximately 100,000 people in the U.S.
The trigeminal nerve is the main sensory nerve in the face associated with triggering excruciating pain for this condition.
Trigeminal neuralgia is typically treated with medication or invasive procedures, including microvascular decompression, radiosurgery, or other percutaneous techniques.
The OneRF trigeminal nerve ablation technology features a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue and relieve severe, chronic pain in the face.
According to the October 2024 report, the trigeminal neuralgia therapeutics market, comprised of pharmacologic and surgical technologies, is expected to grow from $262 million in 2024 to over $416 million by 2030, primarily due to an aging population.
The multi-contact probe is designed for multi-point mapping of pain location, stimulation, and ablation, all using the same electrode and with the safety of temperature-controlled ablation.
These features are also present in the FDA 510(k) cleared OneRF sEEG (brain) Ablation System.
Previously published data have shown that RF ablation offers high initial pain relief rates (~95%) and long-term efficacy, especially with repeat treatments, while maintaining a low complication rate.
Dave Rosa, President and CEO of NeuroOne, stated: "Our OneRF ablation technology platform has already achieved successful commercialization and patient outcomes in lesioning nerve tissue for functional neurosurgical procedures, such as the treatment of epilepsy. Expanding into facial pain broadens the clinical impact of our technology and further validates the versatility and scalability of our platform."
"If cleared by the FDA, we believe there is a potential to generate revenues from trigeminal nerve ablation in late calendar year 2025."
Earlier in April, &nbsp;NeuroOne Medical priced an underwritten registered public offering of 16 million shares at 50 cents per share, around <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44645150/neuroone-medical-technologies-corporation-announces-pricing-of-8-0-million-public-offering-of-comm" rel="noreferrer noopener">$8 million in gross proceeds</a>.
Price Action: NMTC stock closed at $0.54 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44938778/danaher-pricing-strategy-key-to-navigating-tariff-challenges-analyst" target="_blank" rel="noreferrer noopener">Danaher Pricing Strategy Key To Navigating Tariff Challenges: Analyst</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

NMTC

EXCLUSIVE: NeuroOne Submits FDA Marketing Application For OneRF Trigeminal Nerve Ablation System For Facial Pain

EXCLUSIVE: NeuroOne Tells Benzinga Co. Completes FDA Submission For The OneRF Trigeminal Nerve Ablation System To Treat Facial Pain, Says 'Submission Completed Earlier Than Anticipated'

Baird analyst Ben Kallo maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and lowers the price target from $370 to $320.

Baird Maintains Outperform on Tesla, Lowers Price Target to $320

Ahead of Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) first-quarter earnings, this analyst expects Google's parent to deliver on the advertising revenue and expects an "earnings surprise."
What Happened: The Chairman and Founder of Navellier &amp; Associates, Louis Navellier, spoke about Alphabet's first quarter forecast in his podcast ‘Market Buzz'.
&#8220;Well, their sales are forecasted to go up 10.7%, and earnings are forecast to grow 7%. Google does not provide any guidance whatsoever, but it has a very good earnings surprise history. I think what everybody&#8217;s going to be looking at is their advertising revenue very carefully," he said.
According to him, March's strong retail sales will help push Google's<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44909414/google-parent-alphabets-topline-can-withstand-pressure-in-uncertain-macro-scenario-compared-to-peers-analyst"> advertising revenue</a> in the said quarter. &#8220;Based on the strong retail sales we had in March, the strongest in two years, I would think Google&#8217;s advertising revenue would pick up.&#8221;
Last week, a <a href="https://www.benzinga.com/news/legal/25/04/44876356/google-scores-partial-win-in-antitrust-case-but-faces-setback-on-publisher-tools">U.S. District Judge ruled</a> that the Department of Justice won its antitrust case against Alphabet&#8217;s Google, finding the company illegally monopolized advertising technology. 
The ruling concluded that Google engaged in anticompetitive practices for over a decade by bundling its publisher ad server and ad exchange to maintain its monopoly in those open-web display ad markets.
Navellier added, &#8220;The only glitch is, of course, the Department of Justice has won a suit against them to break them up. You know, breaking up Google is kind of like a dog catching a car. I mean, what does the dog do now? They&#8217;re trying to appease the government, and I&#8217;m sure with Trump in it&#8217;s going to be a little different, but I think they&#8217;re trying to spin off Chrome, so we&#8217;ll see what happens, but Google normally beats.&#8221;
See Also: <a href="https://www.benzinga.com/25/04/44945402/wedbushs-dan-ives-raises-teslas-price-target-to-350-as-musk-promises-to-significantly-reduce-doge-time">Wedbush&#8217;s Dan Ives Raises Tesla&#8217;s Price Target To $350 As Elon Musk Promises To &#8216;Significantly&#8217; Reduce DOGE Time</a>
Why It Matters: The company will be reporting its first-quarter earnings on April 24. Alphabet's technical charts indicated that its premarket price of $157.66 per share at the time of the publication was above its short-term simple daily moving averages but below its long-term averages.
The relative strength index of 43.78 was neutral, whereas its MACD line was at negative 4.04. However, its 12-day exponential moving average was above the 26-day EMA, with a positive histogram of 0.47, indicating a bullish trend.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-1024x576.png" alt="" class="wp-image-883854" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The stock was up 2.44% in premarket, but it has fallen by 19.27% on a year-to-date basis. It was 3.76% lower over the year.
Benzinga Edge Stock Rankings shows that GOOG had a weaker price trend over the short, medium, and long term. Its momentum ranking was moderate at the 48.43 percentile, whereas its value ranking was also moderate; the details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>. 
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/report/TSLA"><img loading="lazy" decoding="async" width="1024" height="146" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-1024x146.png" alt="" class="wp-image-883853" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-1024x146.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE.png 1206w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was up 2.50% to $540.42, while the QQQ advanced 3.20% to $457.91, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44945107/bearish-charts-and-upbeat-q1-estimates-heres-how-chipotle-stock-is-doing-after-recent-pric">Chipotle Stock Faces Bearish Charts Despite Upbeat Q1 Estimates And Price Target Revisions</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Earnings Beats

Earnings Misses

Market Summary

Broad U.S. Equity ETFs

Guidance

Futures

Technicals

ETFs

GOOG

GOOGL

NFLX

'Google Normally Beats,' Says Analyst Expecting Sundar Pichai-Led Company's Ad Revenue To 'Pick Up' In Q1: Here's What Alphabet's Chart Shows Ahead Of Earnings

William Blair analyst Brian Drab upgrades Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) from Market Perform to Outperform.

William Blair Upgrades Valmont Industries to Outperform

SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics &amp; Orthotics Group LLC ("Bionic P&amp;O"), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego&#xAE; Personal device distributor.

EKSO

Ekso Bionics Holdings Selects Bionic Prosthetics & Orthotics Group As Non-Exclusive Ekso Indego Personal Device Distributor

Baird analyst Michael Halloran maintains Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Outperform and lowers the price target from $114 to $107.

Baird Maintains Outperform on Pentair, Lowers Price Target to $107

Newly allowed patent extends Wearable Devices' innovative gesture technology into the domain of voice control
YOKNEAM ILLIT, ISRAEL, April 23, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the "Company" or "Wearable Devices") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>, WLDSW))), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, today announced that the United States Patent and Trademark Office has allowed its patent titled "Gesture and Voice-Controlled Interface Device."
This patent represents a significant advancement in the Company's strategic intellectual property ("IP") portfolio, strengthening global protection for its core innovations in wearable bio-potential sensors. The Company's IP strategy includes patent families designed to protect a wide spectrum of future applications, ensuring agility in response to emerging global market needs.

Comments

Battery Future Acquisition Corp Class A

뉴스

에 대한 최신 뉴스 Battery Future Acquisition Corp Class A (OTC:BFACF) 주식

뉴스

파트너 / 기고자

벤징가 글로벌